The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada

Journal of Medical Economics ◽

10.3111/13696998.2016.1164174 ◽

2016 ◽

Vol 19 (7) ◽

pp. 718-727 ◽

Author(s):

Wenqing Su ◽

Anuraag Kansal ◽

Colin Vicente ◽

Baris Deniz ◽

Sujata Sarda

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The Cost Effectiveness of BG-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Value in Health ◽

10.1016/j.jval.2013.08.1826 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623 ◽

Author(s):

W. Su ◽

A. Walker ◽

S. Sarda ◽

A.R. Kansal ◽

C. Vicente ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.03.356 ◽

2014 ◽

Vol 17 (3) ◽

pp. A60-A61 ◽

Author(s):

J.A. Mauskopf ◽

M. Fay ◽

R. Iyer ◽

T. Livingston

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy

Value in Health ◽

10.1016/j.jval.2015.09.2598 ◽

2015 ◽

Vol 18 (7) ◽

pp. A697 ◽

Author(s):

G Furneri ◽

L Santoni ◽

C Marchesi ◽

S Iannazzo ◽

P Cortesi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Versus Glatiramer Acetate For The Treatment Of Relapsing-Remitting Multiple Sclerosis In The Chilean National Health Fund (Fonasa)

Value in Health ◽

10.1016/j.jval.2016.09.491 ◽

2016 ◽

Vol 19 (7) ◽

pp. A431

Author(s):

C Noda ◽

JA de Anda ◽

P Anaya ◽

P Serafini ◽

M Machado

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

National Health ◽

Dimethyl Fumarate ◽

Health Fund ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The Cost-Effectiveness Of Delayed Release Dimethyl Fumarate Versus Glatiramer Acetate For The Treatment Of Relapsing-Remitting Multiple Sclerosis In The Mexican Social Security Institute (Imss)

Value in Health ◽

10.1016/j.jval.2016.09.494 ◽

2016 ◽

Vol 19 (7) ◽

pp. A432

Author(s):

JA de Anda ◽

C Noda ◽

P Anaya ◽

A Azamar ◽

M Machado ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Social Security ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis ◽

Social Security Institute

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2015.09.2931 ◽

2015 ◽

Vol 18 (7) ◽

pp. A755 ◽

Author(s):

D Gasche ◽

G Restovic ◽

V Casado ◽

P Ramírez-Boix ◽

J Martínez Lopez

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-world EFFECT Study

10.26226/morressier.59a3e8b6d462b8028d8951f5 ◽

2017 ◽

Author(s):

Jacob Sloane

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Dimethyl Fumarate ◽

Effect Study ◽

The Real ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286420968357 ◽

2020 ◽

Vol 13 ◽

pp. 175628642096835

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Safety And Efficacy ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.1080/13696998.2016.1258366 ◽

2016 ◽

Vol 20 (3) ◽

pp. 297-302 ◽

Author(s):

Duygu Bozkaya ◽

Terrie Livingston ◽

Kristen Migliaccio-Walle ◽

Tanner Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text